Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Roswell Park Cancer Institute
DescriptionCancer vaccine comprising SVN53-67/M57-KLH, a peptide mimic targeting survivin (BIRC5), in adjuvant Montanide ISA 51
Molecular Target Survivin (BIRC5)
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase I
Standard IndicationBrain cancer
Indication DetailsTreat brain cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today